Search for: "Sanofi"
Results 181 - 200
of 1,195
Sorted by Relevance
|
Sort by Date
4 Nov 2010, 9:59 pm
Sanofi sued Apotex in the U.S. [read post]
11 Dec 2006, 12:59 am
Sanofi v. [read post]
10 Sep 2009, 4:53 pm
The appellate ruling comes too late to keep generic manufacturers of the colon cancer drug Eloxatin out of the market, but the Federal Circuit found that a lower court judge interpreted Sanofi's patent incorrectly when he cleared the way for its rivals. [read post]
15 Mar 2016, 9:00 am
On March 4, 2016, the Second Circuit affirmed the dismissal of two related securities actions against Sanofi Pharmaceuticals, its predecessor Genzyme Corporation, and three company executives (collectively, “Sanofi”). [read post]
18 Dec 2014, 4:43 pm
A statement by Sanofi, of course, denied retaliating against Ponte. [read post]
21 Jul 2009, 9:28 pm
By Suresh Pillai -- Judge Denies Attorneys Fees to Sandoz in Dispute with Sanofi-Aventis The U.S. [read post]
14 Jul 2009, 9:55 pm
In response to Sanofi's and Debiopharm's complaint, Ebewe... [read post]
18 Oct 2011, 10:43 am
By Dennis Crouch Sanofi-Aventis v. [read post]
10 Dec 2006, 12:57 pm
Sanofi v. [read post]
17 Nov 2017, 11:00 am
The Federal Circuit heard the case of Sanofi v. [read post]
25 Jun 2021, 4:15 am
LLC (Sanofi). [read post]
15 May 2023, 1:47 am
Sanofi appealed the decisions to the Supreme Court, but the appeals were rejected on April 24, 2020, and Sanofi was forced to stop its sale of Praluent® entirely in Japan. [read post]
26 Mar 2023, 9:07 pm
Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. [read post]
5 Feb 2023, 9:37 pm
Noonan -- Facing what is likely to be something of an uphill battle in seeking to have the Federal Circuit's decision against it in Amgen v Sanofi overturned before a not always patent-friendly Supreme Court, Amgen in late December filed its opening brief addressing the Question Presented in the granted certiorari petition: Whether enablement is governed by the statutory requirement that the specification teach those skilled in the art to "make and use" the invention, 35… [read post]
14 Mar 2023, 8:58 pm
Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. [read post]
27 Mar 2023, 8:50 pm
Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. [read post]
28 Apr 2015, 2:36 am
A court ruling has revealed that the Commonwealth of Australia (i.e. the Federal Government) is seeking to recover $60 million it considers has been ‘overpaid’ for the anti-clotting drug marketed by Sanofi (formerly Sanofi-Aventis) and Bristol-Meyers Squibb under the brand name PLAVIX: Commonwealth of Australia v Sanofi-Aventis [2015] FCA 384.Sanofi was the owner of Australian Patent No. 597784, which includes claims directed to the compound having the… [read post]
6 Oct 2021, 12:59 pm
But Mylan relied on Sanofi’s internal documents reporting Sanofi market research, which were admissible as business records and party admissions. [read post]
20 Aug 2010, 4:47 am
Judge Gregory Sleet of the US District Court for the District of Delaware lately decided in favor of Sanofi-Aventis in Uroxatral patent lawsuit and ruled that Sanofi’s US Patent Number 4,661,491 is valid and infringed by generic alfuzosin versions from Aurobindo Pharma and Torrent Pharma Inc. [read post]
11 Apr 2011, 12:57 pm
See Sanofi-Aventis v. [read post]
